Semax — Research Summary
Overview
Semax is a synthetic heptapeptide analog of ACTH 4-10, developed in Russia where it has been studied for nootropic applications. It lacks hormonal activity and has been the subject of research examining neurotrophic factor expression. Semax was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a synthetic analog of the adrenocorticotropic hormone (ACTH) fragment 4-10. Unlike the parent hormone, Semax has been documented to lack corticotropic activity, meaning it does not stimulate cortisol production or affect the hypothalamic-pituitary-adrenal axis in the manner of full-length ACTH. This selective modification has allowed researchers to study melanocortin receptor interactions independently of hormonal stress responses. The peptide has been the subject of extensive investigation in Russian scientific literature, with studies examining its effects on neurotrophic factor expression, particularly brain-derived neurotrophic factor (BDNF) and its receptor TrkB. Research methodologies have included intranasal administration paradigms, behavioral testing batteries, electrophysiological recordings, and molecular analyses of gene expression in hippocampal and cortical tissue. The compound's documented stability and favorable pharmacokinetic profile in preclinical models have contributed to sustained research interest.
Compound Profile
The following specifications characterize the Semax research compound as supplied for laboratory investigation purposes.
| Compound Name | Semax |
| Designation | Semax — 5 mg |
| Sequence / Structure | Met-Glu-His-Phe-Pro-Gly-Pro (Heptapeptide, ACTH 4-10 analog) |
| Purity | ≥99% |
| Form | Lyophilized powder |
| Vial Size | 5mg |
| Storage | Refrigerated after reconstitution |
| Research Category | Neuropeptide Research |
| Series | Neuro Series |
| SKU | SX-5 |
Published Research
The following findings have been documented in peer-reviewed publications and scientific literature. These summaries reflect reported observations and are presented for informational purposes in support of laboratory research activities.
- Research published in Russian pharmacology journals documented that Semax increases BDNF (brain-derived neurotrophic factor) expression in rat hippocampus and cortex following intranasal administration.
- Studies have examined Semax's effects on attention, memory, and learning processes in various experimental models, with researchers noting modulation of dopaminergic and serotonergic systems.
- Research has documented Semax's favorable safety profile with minimal reported adverse effects in clinical observations conducted in Russia.
- Studies have examined potential neuroprotective properties in various experimental stress and injury models.
These findings reflect outcomes observed in controlled research settings and published study protocols. Individual experimental conditions, model organisms, and methodologies varied across studies. Results observed in preclinical and clinical research settings may not be generalizable.
Mechanism of Action
Semax is proposed to influence BDNF signaling and modulate melanocortin receptor activity without affecting cortisol levels. Research suggests involvement in attention and cognitive processing pathways.
The mechanisms described above have been characterized through published research methodologies including receptor binding assays, gene expression analyses, cell culture experiments, and in vivo preclinical models. Mechanistic understanding continues to evolve as additional research is published.
Research Context
Neuropeptide research encompasses the study of short-chain peptides that have been observed to interact with central nervous system pathways, including those involved in neurotrophic factor expression, neurotransmitter modulation, and stress-response regulation. This area of investigation has grown substantially as researchers seek to understand how peptide analogs of endogenous neuropeptides may influence cognitive processes, neuroplasticity, and neuronal resilience in experimental models. The melanocortin system, GABAergic signaling, and brain-derived neurotrophic factor (BDNF) pathways have been identified as key areas of interest. Studies have been conducted using a range of experimental paradigms, including behavioral assays in animal models, electrophysiological recordings, and molecular analyses of gene expression in brain tissue. The field also examines the immunomodulatory properties of certain neuropeptides, reflecting the increasingly recognized connections between immune signaling and nervous system function.
Semax has been studied within this broader research context. The compound is classified under the Neuropeptide Research category and is part of the Neuro Series in the Hot Peps research catalog. Researchers investigating neuropeptide research may find the published findings summarized above relevant to their experimental design and literature review processes.
Key Citations
The following references represent a selection of published studies relevant to Semax research. Full-text articles may be accessed through their respective journal publishers or indexed databases such as PubMed.
- Dolotov OV, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression. Brain Res. 2006;1117(1):54-60
- Ashmarin IP, et al. Nootropic and analgesic effects of Semax. Zh Vyssh Nerv Deiat Im I P Pavlova. 2001;51(4):420-426
This compound is part of the Neuro Stack — cognitive & stress-response pathway focus.
View Kit →Important Notice
Semax is sold exclusively for in vitro research, laboratory use, and scientific investigation purposes. This compound is not intended for human consumption, veterinary use, or any therapeutic application. It is not intended to diagnose, treat, cure, or prevent any disease or medical condition.
All research findings, statistics, and outcomes referenced on this page have been sourced from published peer-reviewed studies and scientific literature. These summaries are provided for informational purposes to support qualified researchers in their laboratory investigations. Results documented in published research were obtained under specific experimental conditions and may not be reproducible in all settings.
Researchers are responsible for ensuring that their use of research compounds complies with all applicable local, state, and federal regulations governing laboratory research materials.
Related Research Insights
Explore the Complete Guide to Research Peptides →Learn More About Peptide Research
All findings referenced on this page reflect outcomes reported in published research studies. This product is sold strictly for in vitro research, laboratory use, and scientific investigation only. Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.